Synairgen (LON:SNG) Reaches New 1-Year Low – Time to Sell?

Shares of Synairgen plc (LON:SNG) hit a new 52-week low during trading on Friday . The stock traded as low as GBX 1.81 ($0.02) and last traded at GBX 2 ($0.02), with a volume of 3416760 shares trading hands. The stock had previously closed at GBX 1.99 ($0.02).

Synairgen Stock Up 0.4 %

The stock has a market capitalization of £4.03 million, a P/E ratio of -66.67 and a beta of -2.23. The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.35 and a current ratio of 6.77. The company’s 50-day moving average price is GBX 3.60 and its 200 day moving average price is GBX 3.96.

About Synairgen

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease.

Synairgen is conducting a double blind, placebo-controlled clinical trial in COVID-19 patients (SG016).